Eyenovia, Inc. (Nasdaq: Eyen)An ophthalmic technological company, announced on June 17, 2025, a private investment of $ 50 million in public equity (financing of pipes) to establish a cryptocurrency reserve strategy focused on the acquisition of media threshing tokens, the native token of the Hyperliquidal Blockchain. Funds will be used to buy more than a million media threshing tokens, positioning Eyenovia as one of the best validators for the hyperliquidal and the first company listed on the US stock market to hold media in its treasury.
The company will issue the convertible convertible action convertible without a vote in approximately 15.4 million ordinary shares to $ 3.25 per share and mandates to buy around 30.8 million shares at the same price, potentially increasing up to $ 150 million if all mandates are exercised. Eyenovia also appointed Hyunsu Jung as director of investments and member of the Board of Directors to direct this strategy and Max Fiege as a strategic advisor to support the media treasury initiative. The Company plans to implement a program of implementation of media threshing via a partnership with Digital anchorage While continuing its main activity, including the development of the device filled with Gen-2 opte, should be registered with the FDA by September 2025.
Eyenovia will find out like Hyperion DEFI With the Ticker symbol Hypdwith the transaction which should close around June 20, 2025. In addition, Avenue capital groupEyenovia’s largest ordinary shareholder has changed the company’s guaranteed debt, extending maturity from November 2025 to July 2028 and reducing the interest rate from 12% to 8%.
Register For TEKEDIA Mini-MBA Edition 17 (June 9 – September 6, 2025)) Today for early reductions. An annual for access to Blurara.com.
Tekedia Ai in Masterclass Business open registration.
Join Tekedia Capital Syndicate and co-INivest in large world startups.
Register become a better CEO or director with CEO program and director of Tekedia.
The implications of the Eyenovia, Inc. (Nasdaq: Eyen) $ 50 million PIPE financing to establish a THRESHING The token treasure reserve and its strategic pivot towards decentralized finance (DEFI) and blockchain are multifaceted, creating both opportunities and risks. This decision also highlights a growing gap between traditional finance and the emerging cryptography / defi sector. Eyenovia’s decision to become the first company listed on the American stock exchange to hold media threshing tokens in its treasure positions it as a pioneer in the adoption of business cryptocurrency. By acquiring more than a million media threshing tokens and becoming a better validator on the hyperliquid blockchain, Eyenovia could benefit from a potential appreciation of the value of media and milestone rewards, diversifying its financial strategy.
The volatility of cryptocurrencies, including threshing media, presents significant financial risks. A sharp decline in the value of media beating could harm Eyenovia’s assessment, especially since the investment of $ 50 million represents a substantial capital allowance for a small capitalization company (market capitalization ~ 50 million dollars before cancellation). A regulatory examination of the SEC or other agencies could also occur, given the new nature of the holding of the crypto as an asset of the Treasury.
By integrating DEFI through media threshing status and validator status, EYENOVIA aims to create a new source of income via ignition rewards and a potential blocchain governance influence. The rebranding to Hyperion DEFI (Ticker: Hypd) signals a long-term commitment to this hybrid model, potentially attracting crypto-vertis investors. This pivot can dilute the main activity of Eyenovia ophthalmic technology, including the Optejet Gen-2 opte system, which is essential for the registration of the FDA by September 2025. Investors expecting a pure-game biotechnology can consider the DEFI strategy as a distraction, which potentially leads to the volatility of the shareholders’ prices.
The financing of pipes, the emission of privileged convertible stocks and the structure of the guarantees could collect up to $ 150 million if they are fully exercised, providing significant capital for the media reserve and current R&D. The amendment of the debt with avenue Capital (extended deadline at July 2028, reduction of the interest rate from 12% to 8%) improves the financial flexibility of Eyenovia. The issue of 15.4 million new shares (plus ~ 30.8 million via mandates) to $ 3.25 per share could result in substantial dilution, which can be depressing the course of action if investors’ confidence passes. The conversion price is close to recent negotiation levels ($ 3.30 to June 17, 2025, by X Posts), increasing the probability of conversion and additional dilution.
Note Hyunsu Jung As director of investments and Max Fiege As the strategic advisor brings an expertise in crypto and deffi to the leadership of Eyenovia, potentially improving the execution of the media threshing strategy. Partnerships with digital anchorage to mark out add credibility. The sudden change in the leadership focused on crypto can raise concerns concerning alignment with the biotechnological mission of Eyenovia. Stakers may wonder if the board of directors and management have the bandwidth to effectively execute the two strategies.
The announcement has generated buzz on platforms like X, some users renting the daring passage of Eyenovia in Defi as a “changing game” for corporate treasury bills. This could attract a new investor base, including crypto enthusiasts and growth -oriented funds. Traditional biotechnology investors can react negatively, perceiving the crypto pivot as a speculative or badly aligned with the expertise of Eyenovia. Articles X show a mixed feeling, some calling it a “desperate movement” for a difficulty biotechnology. The performance of the action will depend on how Eyenovia balances her double identity.
Eyenovia’s strategy underlines a growing gap between traditional finance (tradfi) and the emerging crypto / challenge ecosystem, with implications for the markets, regulations and the behavior of investors. Tradfi emphasizes stability, regulatory compliance and tangible assets. Investors in biotechnology generally appreciate predictable cash flows, milestones of clinical trials and FDA approvals. The main activity of Eyenovia corresponds to this mold, with its opte project targeting a clear need for the market.
Crypto / DEFI prioritizes decentralization, innovation and speculative growth. The media threshing tokens and hyperliquids represent a bet on the disturbing potential of the blockchain, attractive for comfortable investors with high risk and volatility. Eyenovia’s hybrid model tries to fill this ditch, but the risks alienating both camps. Tradfi investors can be wary of the crypto pivot, while DEFI purists can question the role of a biotechnology in the blockchain.
Tradfi works in well -defined dry, FDA and IRS frames. Eyenovia’s biotechnological operations are subject to rigorous monitoring of the FDA, while its public list requires transparent financial reports. Crypto / Defi faces an evolving and fragmented regulatory landscape. The position of the dry on the crypto as a titles remains clear, and the holding of tokens of media could invite to a meticulous examination. Employed awards can also increase tax or accounting issues.
Eyenovia’s decision could encourage regulators to clarify how public companies can integrate crypto into treasury bills, which potentially a previous one. However, unfavorable decisions could affect the Eyenovia strategy or the wider sector. Tradfi institutional investors (for example, common funds, pension funds) dominate biotechnology, promoting long -term stability. The restructuring of the avenue Capital debt suggests the confidence of certain tradfi actors, but others can hesitate.
Crypto / DEFI attracts retail investors, hedge funds and crypto-native funds (for example, via digital anchorage). Articles X indicate retail excitation around media threw, but the institutional adoption of cryptography remains limited. Eyenovia’s actions can see increased volatility as these groups of investors compete. The success of the pipe depends on attracting it user -friendly capital, but the risks of dilution could dissuade both sides.
Tradfi biotechnology actions are assessed with fundamental principles (for example, pipelines, income potential). The Eyenovia Optejet could address a $ 5 billion market, according to analysts’ estimates, but its crypto pivot eclipses this story. Crypto / challenge assessments are often focused on feeling, linked to the usefulness of tokens and the growth of the network. The hyperliquid traction (for example, Validator awards, the case of use of DEFI) could increase the value of hype, benefiting from the Eyenovia Treasury.
Eyenovia’s assessment can decline biotechnological peers, becoming a hybrid game. Success is based on the performance of the media threshing and the optejet stages, creating a complex risk award profile. Eyenovia’s $ 50 million media treasury strategy is a daring bet on the future of Defi, positioning it as a pioneer among public companies. It offers diversification and upward potential, but risks dilution, regulatory obstacles and investors’ skepticism. This decision amplifies the Tradfi-Crypto division, highlighting tensions between stability and innovation, regulations and freedom, and institutional mentalities compared to the mentalities of retail.
